/HRMY
HRMY Stock - Harmony Biosciences Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$35.76-6.56%
$2.51 (-6.56%) • Jan 13
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+29.8%upside
Target: $46.42
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HRMY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$35.40 – $36.12
TARGET (TP)$46.40
STOP LOSS$32.90
RISK/REWARD1:3.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.84
52W High$40.93
52W Low$25.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M |
| Gross Profit | $557.92M | $460.79M | $354.37M | $249.92M | $132.00M |
| Gross Margin | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% |
| Operating Income | $190.83M | $192.03M | $120.19M | $87.53M | $16.99M |
| Net Income | $145.49M | $128.85M | $181.47M | $34.60M | $-36,944,000 |
| Net Margin | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% |
| EPS | $2.56 | $2.17 | $3.07 | $0.60 | $-1.12 |
Company Overview
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HRMYBeat Rate
78%
Last 18 quarters
Avg Surprise
+105.6%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$0.87
Q4 2025
EPS Surprise History
Q1 24
-6.2%
$0.45vs$0.48
Q2 24
+11.7%
$0.67vs$0.60
Q3 24
+433.3%
$0.20vs$-0.06
Q4 24
+17.9%
$0.79vs$0.67
Q1 25
+14.9%
$0.85vs$0.74
Q2 25
+32.2%
$0.78vs$0.59
Q3 25
-12.8%
$0.68vs$0.78
Q4 25
-5.4%
$0.87vs$0.92
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $0.79 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.92 | $0.87 | -5.4% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $0.78 | $0.68 | -12.8% | ✗ MISS |
Q2 2025 | May 6, 2025 | $0.59 | $0.78 | +32.2% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $0.74 | $0.85 | +14.9% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $0.67 | $0.79 | +17.9% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.06 | $0.20 | +433.3% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $0.60 | $0.67 | +11.7% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.48 | $0.45 | -6.2% | ✗ MISS |
Q4 2023 | Oct 31, 2023 | $0.65 | $0.75 | +15.4% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.63 | $0.56 | -11.1% | ✗ MISS |
Q2 2023 | May 2, 2023 | $0.44 | $0.48 | +9.1% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $0.58 | $0.79 | +36.2% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $0.10 | $0.95 | +850.0% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $0.40 | $0.57 | +42.5% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $0.25 | $0.51 | +104.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $0.32 | $0.63 | +96.9% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.27 | $0.51 | +88.9% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $0.19 | $0.54 | +184.2% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about HRMY
What is HRMY's current stock price?
Harmony Biosciences Holdings, Inc. (HRMY) is currently trading at $35.76 per share. The stock has moved -6.56% today.
What is the analyst price target for HRMY?
The average analyst price target for HRMY is $46.40, based on 1 analyst.
What sector is Harmony Biosciences Holdings, Inc. in?
Harmony Biosciences Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HRMY's market cap?
Harmony Biosciences Holdings, Inc. has a market capitalization of $2.06 billion, making it a mid-cap company.
Does HRMY pay dividends?
No, Harmony Biosciences Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$4.27
Mkt Cap: $1.3B
AUPH
Aurinia Pharmaceuticals Inc.
$14.99
Mkt Cap: $2.0B
BHVN
Biohaven Ltd.
$10.97
Mkt Cap: $1.2B
CLDX
Celldex Therapeutics, Inc.
$25.93
Mkt Cap: $1.7B
IMCR
Immunocore Holdings plc
$32.30
Mkt Cap: $1.6B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
MNKD
MannKind Corporation
$5.64
Mkt Cap: $1.7B
NUVB
Nuvation Bio Inc.
$6.55
Mkt Cap: $2.2B
SION
Sionna Therapeutics, Inc.
$36.81
Mkt Cap: $1.6B
VERA
Vera Therapeutics, Inc.
$49.10
Mkt Cap: $3.1B
Explore stocks similar to HRMY for comparison